Cancer Glycogene Discovery Service

Cancer Glycogene Discovery Service

Altered Glycosylation in Cancer

Altered glycosylation is a recognized hallmark of cancer, mediating tumor cell interactions, affecting cell-matrix interactions, leading to harmful metabolism and cell signaling, etc. The cancer genome reveals changes in the expression of some glycosylation-specific genes in cancer. For example, many isoforms of the GALNT and GalNAcT families are absent from healthy tissues but are highly expressed in cancer cells, making them reliable biomarkers for cancer diagnosis, monitoring, and treatment. Considerable work remains devoted to large-scale analysis of glycosylation genes in human tumors to help improve diagnostic methods, treatment standards, and ultimately cancer prevention.

Fig.1 Role of glycans in cancer development and progression. (Pinho & Reis, 2015)Fig.1 Role of glycans in cancer development and progression. (Pinho & Reis, 2015)

Cancer Glycogene Discovery Service at CD BioGlyco

With the advanced Glycogenomics Platform, CD BioGlyco provides clients with comprehensive Expression Profiling services in cancer. We apply various methods to help clients study glycogenes in cancer at an advanced level. Our services include but are not limited to:

Fig.2 Technologies for glycogene expression profiling in cancer. (CD BioGlyco)Fig.2 Technologies for glycogene expression profiling in cancer. (CD BioGlyco)


  • We perform a comprehensive analysis of glycogene expression in cancer to identify their expression signatures and potentially altered glycosylation pathways.
  • We analyze glycogene signatures or the expression levels of the proteins they encode to explore whether they can be used as putative biomarkers.
  • Identification of new specific glycogenes for use in cancer diagnosis and treatment.

Advantages of Us

  • Comprehensive expression analysis of genes in cancer cells through high-throughput technologies such as microarrays and NGS.
  • To further identify glycogene expression signatures in cancer cells, we perform hierarchical clustering analysis on the samples after removing low-expressed glycogenes.
  • An experienced team of scientists and a high-quality technical platform guarantee your services.

With an advantageous glycogenomics platform, CD BioGlyco uses a variety of expression analysis technologies to help clients analyze glycosylation genes in cancer to explore new biomarkers. If you have related project needs, please feel free to contact us.


  1. Pinho, S.S.; Reis, C.A. Glycosylation in cancer: mechanisms and clinical implications. Nature Reviews Cancer. 2015, 15(9): 540-555.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.